Form 4: Terns Pharmaceuticals CFO Boosts Stake with Open Market Stock Purchases

Terns Pharmaceuticals' Chief Financial Officer, Andrew Gengos, acquired 10,000 shares of common stock through open market purchases on June 27, 2025, increasing his direct beneficial ownership to 25,000 shares.

Summary

• Andrew Gengos, Chief Financial Officer of Terns Pharmaceuticals, Inc. (TERN), acquired common stock on June 27, 2025.
• Gengos purchased 5,000 shares at a price of $3.9267 per share.
• On the same date, an additional 5,000 shares were purchased at $3.9299 per share.
• These transactions increased his direct beneficial ownership in Terns Pharmaceuticals to 25,000 shares.
• The acquisitions were executed pursuant to a Rule 10b5-1 plan.

Sentiment

Score: 7

Explanation: The Chief Financial Officer's open market purchase of company stock indicates a degree of confidence in the company's valuation and future prospects.

Positives

• Chief Financial Officer Andrew Gengos increased his direct beneficial ownership in Terns Pharmaceuticals by acquiring 10,000 shares, signaling confidence in the company's future.
• The insider purchases were made through open market transactions, indicating a direct investment by management.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders may view the insider purchase as a positive signal of management's confidence in the company's future performance and valuation.

Key Dates

Recommendation

Keywords

Terns Pharmaceuticals, TERN, Andrew Gengos, CFO, insider trading, stock purchase, beneficial ownership, Form 4, SEC filing, Rule 10b5-1